Most researchers verified the efficiency of SGLT2 inhibitors in patients with comorbidities of DM2 and NAFLD, but for empagliflozin, the ability to improve the hepatic state was proven in patients with NAFLD but without diabetes [107]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.